Real-World Use Of Ultrathin-Strut Biodegradable Polymer–Coated Sirolimus-Eluting Stents In Patients With Coronary Artery Disease: 6-Month Clinical Outcomes
Authors Ajmera P, Pothineni R, Chawla KK, Mantravadi SS, Jariwala PV, Vijan V, Vijan V
Received 6 February 2019
Accepted for publication 16 September 2019
Published 18 October 2019 Volume 2019:15 Pages 439—447
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Professor Magnus Bäck
Prakash Ajmera,1 Ramesh Pothineni,2 Kamal Kumar Chawla,1 Sai Sudhakar Mantravadi,3 Pankaj Vinod Jariwala,4 Vinod Vijan,5 Vikrant Vijan5
1Department of Cardiology, Malla Reddy Narayana Multispeciality Hospital, Hyderabad, Telangana 500055, India; 2Department of Cardiology, Ramesh Hospitals, Vijayawada, Andhra Pradesh 520008, India; 3Department of Cardiology, Gleneagles Global Hospital, Hyderabad, Telangana 500004, India; 4Department of Cardiology, Yashoda Hospitals, Somajiguda, Hyderabad, Telangana, 500082, India; 5Department of Cardiology, Vijan Cardiac and Critical Care Centre, Nashik, Maharashtra 422005, India
Correspondence: Prakash Ajmera
Malla Reddy Narayana Multispeciality Hospital, 1-1-216 Suraram Crossroads, Jeedimetla, Hyderabad, Telangana 500055, India
Tel +91 9985401317
Background: Although a number of drug-eluting stents have been developed with different design, composition, and polymers, the search for an ideal drug-eluting stent is ongoing. The Tetriflex (Sahajanand Medical Technology, Surat, India) is a newer-generation, ultrathin (60 μm) biodegradable polymer–coated sirolimus-eluting stent (SES) designed with a unique long dual Z-link on a cobalt–chromium alloy. The present registry aimed to evaluate the safety and clinical outcomes of the Tetriflex SES at 6-month post-implantation.
Methods: This was an investigator-initiated, retrospective, multicenter, single-arm, observational registry conducted at five tertiary-care centers in India. A total of 1,269 consecutive patients with coronary artery disease who underwent implantation of at least one Tetriflex SES between March 2017 and March 2018 were included. The primary outcome was considered a composite of cardiac death, myocardial infarction and target-lesion revascularization (TLR) at 6-month follow-up. Stent thrombosis was evaluated as a safety outcome at 6-month follow-up.
Results: The mean age of patients was 54.99±10.80 years. Among 1,515 lesions treated with 1,682 Tetriflex SES, 58.3% were type C lesions. Six-month follow-up was done for 1,245 of 1,269 (98.1%) patients. At 6 months, composite events had occurred in 31 (2.5%) patients, consisting of ten (0.8%) cardiac deaths, 16 (1.3%) myocardial infarctions, and five (0.4%) TLRs. Stent thrombosis was observed in seven (0.56%) cases at 6 months. A subgroup analysis between diabetic and nondiabetic patients did not reveal any statistically significant difference for clinical outcomes at 6-month follow-up.
Conclusion: The results of the current registry outline the safety and effectiveness of the Tetriflex SES in real-world patients, as it displayed favorable clinical outcomes at 6-month follow-up, with low incidence of TLR and stent thrombosis.
Keywords: biodegradable polymer, drug-eluting stents, sirolimus, ultrathin strut
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]